-

10:00:51 PM

AGNPF Stock News

AGNPF - Algernon Pharmaceuticals, Inc.

10/13/21 7:00 AM

OTC : AGNPF

clinical trial

Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has filed a scientific advice meeting request

RHEA-AI

neutral

10/08/21 7:00 AM

OTC : AGNPF

clinical trial

Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has filed a pre-IND (Investigational New Drug)

RHEA-AI

neutral

09/22/21 7:30 AM

OTC : AGNPF

Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has filed a pre-IND (Investigational New Drug)

RHEA-AI

neutral

09/22/21 7:00 AM

OTC : AGNPF

management

Algernon Pharmaceuticals Announces the Appointment of Dr. Mark Williams to the Board of Directors

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Dr. Mark Williams has been appointed as a member

RHEA-AI

neutral

09/20/21 7:00 AM

OTC : AGNPF

clinical trial

Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.

Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) (FRANKFURT: AGW) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to file a pre-IND (Investigational New

RHEA-AI

neutral

09/09/21 11:46 AM

OTC : AGNPF

Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that its CEO Christopher J. Moreau will be delivering

RHEA-AI

neutral

09/09/21 7:00 AM

OTC : AGNPF

management

Algernon Pharmaceuticals Announces Appointment of Harry Bloomfield, QC. as a New Board Director and Chairman

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that Harry Bloomfield, QC. has been appointed as a new

RHEA-AI

neutral

09/07/21 7:30 AM

OTC : AGNPF

clinical trial

Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has confirmed in its own preclinical study,

RHEA-AI

very positive

08/11/21 7:00 AM

OTC : AGNPF

management

Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has initiated an NP-120 (“Ifenprodil”)

RHEA-AI

neutral

08/09/21 7:00 AM

OTC : AGNPF

Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has signed an exclusive licensing agreement

RHEA-AI

neutral